HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies

Seminars in Thrombosis and Hemostasis

Volumn 43, Issue 6, 2017, Pages 562-571

  Schreiber, Karen ^a,b   Breen, Karen ^a   Cohen, Hannah ^c   Jacobsen, Soren ^b   Middeldorp, Saskia ^d   Pavord, Sue ^e   Regan, Lesley ^f   Roccatello, Dario ^g   Robinson, Susan E ^a   Sciascia, Savino ^g   Seed, Paul T ^h   Watkins, Linda ⁱ   Hunt, Beverley J ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f ST MARY S HOSPITAL   (United Kingdom)

^g UNIVERSITY OF TURIN   (Italy)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ LIVERPOOL WOMEN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

antiphospholipid antibodies; antiphospholipid syndrome; hydroxychloroquine; obstetric antiphospholipid syndrome; pregnancy

Indexed keywords

HYDROXYCHLOROQUINE; PHOSPHOLIPID ANTIBODY; PLACEBO; ENZYME INHIBITOR;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECLAMPSIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL ANALYSIS; CLINICAL TRIAL; IMMUNOLOGY; METHODOLOGY; OUTCOME ASSESSMENT; PREGNANCY; PROCEDURES;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; OUTCOME ASSESSMENT (HEALTH CARE); PREGNANCY; PREGNANCY OUTCOME; RESEARCH DESIGN;

EID: 85020704652     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0037-1603359     Document Type: Article

References (64)

1. Miyakis S. Lockshin M. D. Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: 2006; 4 02 295 306
2. Bramham K. Hunt B. J. Germain S., et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus: 2010; 19 01 58 64
3. Bouvier S. Cochery-Nouvellon E. Lavigne-Lissalde G., et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood: 2014; 123 03 404 413
4. Mak A. Cheung M. W. Cheak A. A. Ho R. C. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford): 2010; 49 02 281 288
5. Bramham K. Thomas M. Nelson-Piercy C. Khamashta M. Hunt B. J. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood: 2011; 117 25 6948 6951
6. Branch D. W. Peaceman A. M. Druzin M., et al. The Pregnancy Loss Study Group. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol: 2000; 182 (1 Pt 1): 122 127
7. Triolo G. Ferrante A. Ciccia F., et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum: 2003; 48 03 728 731
8. Sciascia S. Branch D. W. Levy R. A., et al. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb Haemost: 2016; 115 02 285 290
9. Erkan D. Aguiar C. L. Andrade D., et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev: 2014; 13 06 685 696
10. Wallace D. J. The history of antimalarials. Lupus: 1996; 5 01 S2 S3
11. Wallace D. J. Gudsoorkar V. S. Weisman M. H. Venuturupalli S. R. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol: 2012; 8 09 522 533
12. Müller-Calleja N. Manukyan D. Canisius A. Strand D. Lackner K. J. Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. Ann Rheum Dis: 2016;; annrheumdis-2016-210012
13. Pierangeli S. S. Vega-Ostertag M. Harris E. N. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res: 2004; 114 (5-6): 467 476
14. Rand J. H. Wu X. X. Quinn A. S., et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood: 2010; 115 11 2292 2299
15. Giannakopoulos B. Krilis S. A. The pathogenesis of the antiphospholipid syndrome. N Engl J Med: 2013; 368 11 1033 1044
16. Sorice M. Longo A. Capozzi A., et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum: 2007; 56 08 2687 2697
17. López-Pedrera C. Buendía P. Cuadrado M. J., et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum: 2006; 54 01 301 311
18. Ritis K. Doumas M. Mastellos D., et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol: 2006; 177 07 4794 4802
19. Vega-Ostertag M. Casper K. Swerlick R. Ferrara D. Harris E. N. Pierangeli S. S. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum: 2005; 52 05 1545 1554
20. Wolberg A. S. Roubey R. A. Mechanisms of autoantibody-induced monocyte tissue factor expression. Thromb Res: 2004; 114 (5-6): 391 396
21. Kornberg A. Blank M. Kaufman S. Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol: 1994; 153 03 1328 1332
22. Reverter J. C. Tàssies D. Font J., et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum: 1998; 41 08 1420 1427
23. Girardi G. Berman J. Redecha P., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest: 2003; 112 11 1644 1654
24. Edwards M. H. Pierangeli S. Liu X. Barker J. H. Anderson G. Harris E. N. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation: 1997; 96 12 4380 4384
25. Mulla M. J. Brosens J. J. Chamley L. W., et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol: 2009; 62 02 96 111
26. Albert C. R. Schlesinger W. J. Viall C. A., et al. Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am J Reprod Immunol: 2014; 71 02 154 164
27. Mulla M. J. Myrtolli K. Brosens J. J., et al. Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity. Am J Reprod Immunol: 2010; 63 05 339 348
28. Levine R. J. Maynard S. E. Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med: 2004; 350 07 672 683
29. Levine R. J. Lam C. Qian C., et al. CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med: 2006; 355 10 992 1005
30. Kim M. Y. Buyon J. P. Guerra M. M., et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol: 2016; 214 01 108.e1 108.e14
31. Pierangeli S. S. Chen P. P. Raschi E., et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost: 2008; 34 03 236 250
32. Holers V. M. Girardi G. Mo L., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med: 2002; 195 02 211 220
33. Pierangeli S. S. Girardi G. Vega-Ostertag M. Liu X. Espinola R. G. Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum: 2005; 52 07 2120 2124
34. Fischetti F. Durigutto P. Pellis V., et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood: 2005; 106 07 2340 2346
35. Meroni P. L. Borghi M. O. Raschi E. Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol: 2011; 7 06 330 339
36. Breen K. AS. Seed P. Parmar K. Moore G. W. Stuart-Smith S. E. Hunt B. J. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost: 2012; 107 03 423 429
37. Oku K. Amengual O. Zigon P. Horita T. Yasuda S. Atsumi T. Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody. Rheumatology (Oxford): 2013; 52 10 1775 1784
38. Bertolaccini M. L. Contento G. Lennen R., et al. Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. J Autoimmun: 2016; 75 30 38
39. Prinz N. Clemens N. Canisius A. Lackner K. J. Endosomal NADPH-oxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Lessons from the antiphospholipid syndrome. Thromb Haemost: 2013; 109 03 525 531
40. Müller-Calleja N. Köhler A. Siebald B., et al. Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome. Thromb Haemost: 2015; 113 05 1071 1083
41. U.S. Food and Drug Administration. Lupus therapies continue to evolve. Available at: https://www.fda.gov/forconsumers/consumerupdates/ucm398682.htm. Accessed May 27, 2017
42. Molad Y. Gorshtein A. Wysenbeek A. J., et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus: 2002; 11 06 356 361
43. Fessler B. J. Alarcón G. S. McGwin G. Jr., et al. LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum: 2005; 52 05 1473 1480
44. Ruiz-Irastorza G. Egurbide M. V. Pijoan J. I., et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus: 2006; 15 09 577 583
45. Group T. CHS.; The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med: 1991; 324 03 150 154
46. Parke A. L. Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol: 1988; 15 04 607 610
47. Parke A. Antimalarial drugs and pregnancy. Am J Med: 1988; 85 (4A): 30 33
48. Ostensen M. Khamashta M. Lockshin M., et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther: 2006; 8 03 209
49. Andreoli L. Bertsias G. K. Agmon-Levin N., et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. 2017; 76 03 476 485
50. Flint J. Panchal S. Hurrell A., et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford): 2016; 55 09 1693 1697
51. Schmidt-Tanguy A. Voswinkel J. Henrion D., et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost: 2013; 11 10 1927 1929
52. Hospital for Special Surgery, New York. Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients. ClinicalTrials.gov identifier: NCT01784523. Available at: https://clinicaltrials.gov/ct2/show/NCT01784523. Accessed May 14, 2017
53. Mekinian A. Lazzaroni M. G. Kuzenko A., et al. SNFMI and the European Forum on Antiphospholipid Antibodies. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. Autoimmun Rev: 2015; 14 06 498 502
54. Sciascia S. Hunt B. J. Talavera-Garcia E. Lliso G. Khamashta M. A. Cuadrado M. J. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol: 2016; 214 02 273.e1 273.e8
55. Schreiber K. Sciascia S. Breen K., et al. Proposed trial: hypatia-a prospective randomised controlled trial of hydroxychoroquine versus placebo during pregnancy in women with antiphospholipid antibodies. J Thromb Haemost: 2015; 13 281
56. Pengo V. Tripodi A. Reber G., et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost: 2009; 7 10 1737 1740
57. Devreese K. M. Pierangeli S. S. de Laat B. Tripodi A. Atsumi T. Ortel T. L.; Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost: 2014; 12 05 792 795
58. MHRA. MHRA- Clinical Trial Authorisation. 2017. Available at: http://www.hra.nhs.uk/research-community/the-review-process/mhra-clinical-trial-authorisation/. Accessed May 27, 2017
59. Gardiner C. Hills J. Machin S. J. Cohen H. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus: 2013; 22 01 18 25
60. Arachchillage D. R. Machin S. J. Mackie I. J. Cohen H. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thromb Haemost: 2015; 113 01 13 19
61. Ruffatti A. Olivieri S. Tonello M., et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost: 2008; 6 10 1693 1696
62. Boffa M. C. Boinot C. De Carolis S., et al. Laboratory criteria of the obstetrical antiphospholipid syndrome. Data from a multicentric prospective European women cohort. Thromb Haemost: 2009; 102 01 25 28
63. Cohn D. M. Goddijn M. Middeldorp S. Korevaar J. C. Dawood F. Farquharson R. G. Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost: 2010; 8 10 2208 2213
64. Kaandorp S. P. Goddijn M. van der Post J. A., et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med: 2010; 362 17 1586 1596